536742-64-0

Usage

Uses

1-(4-Bromophenyl)-3-pyrrolidinol used in antitumor studies.

Upstream product

• 3068-00-6 D,L-1,2,4-butanetriol 
• 106-40-1 4-bromo-aniline 
• 40499-83-0 pyrrolidin-3-ol 
• 589-87-7 1,4-bromoiodobenzene 
• 19398-47-1 1,4-dibromo-2-butanol 

Downstream Products

• 1046816-78-7 1-(4-bromophenyl)pyrrolidin-3-yl methanesulfonate 
• 536743-16-5 [1-(4-bromo-phenyl)-pyrrolidin-3-yl]-cyano-acetic acid ethyl ester 
• 536742-81-1 3-dicyanomethylene-1-(4-bromophenyl)pyrrolidine 
• 536743-23-4 2-[1-(4-bromo-phenyl)-pyrrolidin-3-yl]-malononitrile 
• 536742-72-0 1-(4-bromophenyl)pyrrolidine-3-one 

Relevant academic research and scientific papers

Ruthenium catalyzed amination cyclization of 1,2,4-butanetriol with primary amines: A borrowing hydrogen strategy for 3-pyrrolidinol synthesis

A ruthenium based catalytic system ([Ru(p-cymene)Cl2]2/XantPhos with substoichiometric Cs2CO3) has been established to effectively achieve the first direct amination cyclization of 1,2,4-butanetriol with primary

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), wherein the groups and radicals A, B, W, X, Y, Z, R1, and R2 have the meanings indicated in claim 1. The invention further relates to medicaments containing at least one inventive alkyne. The disclosed medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, particularly adiposity and diabetes, as a result of the MCH receptor antagonistic activity thereof.

Non-classical antifolates, 5-(N-phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and 2,4-Diamino-6(5H)-oxopyrimidines, synthesis and antitumor studies

A series of non-classical antifolates, namely 5-(N-phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines (25a-i) and 2,4-diamino-(N-phenylpyrrolidin-3-yl)-6(5H)-oxopyrimidines (26a,b,c,f,h,i) was synthesized and evaluated for their in vitro cytotoxicity. React